5-LOX in Alzheimer’s Disease: Potential Serum Marker and In Vitro Evidences for Rescue of Neurotoxicity by Its Inhibitor YWCS

  • Shashank Shekhar
  • Saroj Kumar Yadav
  • Nitish Rai
  • Rahul Kumar
  • Yudhishthir Yadav
  • Manjari Tripathi
  • Aparajit B. Dey
  • Sharmistha Dey
Article

Abstract

The inflammatory process plays a key role in neurodegenerative disorder. The inflammatory molecule, 5-lipooxygenase (5-LOX), protein is involved in the pathologic phenotype of Alzheimer’s disease (AD) which includes Aβ amyloid deposition and tau hyperphosphorylation. This study determined the level of 5-LOX in serum of AD patients, mild cognitive impairment (MCI) patients, and the normal elderly, and the rescue effect by YWCS, a peptide inhibitor of 5-LOX on neurotoxicity by Aβ amyloid25–35 (Aβ25–35) in neuroblastoma cells. The concentration of serum 5-LOX was estimated by surface plasmon resonance and western blot. The neuroprotective effect of 5-LOX peptide inhibitor YWCS in Aβ25–35-induced neurotoxicity was analyzed by MTT assay and western blotting. We found significant upregulated serum 5-LOX in AD patients and also in MCI patients compared to the normal control group. The peptide inhibitor of 5-LOX, YWCS, prevented the neurotoxic effect of Aβ25–35 by reducing the expression of γ-secretase as well as p-Tau181 in SH-SY5Y cells. However, YWCS was nontoxic towards normal HEK cells. The differential expression of serum 5-LOX among the study groups suggests it can be one of potential serum protein marker and a therapeutic regimen for AD and MCI. The negative correlation with neuropsychological parameters, i.e., MoCA and HMSE, increases its importance and makes it useful during the clinical setup which is very needful in developing countries. Peptide YWCS can serve as a new platform as a 5-LOX inhibitor which can prevent neurotoxicity developed in AD.

Keywords

Alzheimer’s disease 25–35 Surface plasmon resonance Neurodegenerative disease Neuroprotective 

Notes

Acknowledgements

The authors acknowledge the Research Section, All India Institute of Medical Sciences, for providing the intramural grant and funds for the consumable items and DST, government of India, for the fellowship of Nitish Rai.

Compliance with Ethical Standards

The Ethics Committee of AIIMS approved the study protocol (IESC/T-439/23.12.2014). Informed consent in writing was obtained from the controls, patients, or their attendants (if a patient is incapable of making a signature). The study was carried out as per the guidelines of the Ethics Committee.

References

  1. 1.
    Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT (2011) Neuropathological alterations in Alzheimer disease. Cold Spring HarbPerspect Med 1:a006189. doi: 10.1101/cshperspect.a006189 Google Scholar
  2. 2.
    Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239–259. doi: 10.1007/BF00308809 CrossRefPubMedGoogle Scholar
  3. 3.
    Phillip F, Giannopoulos YB, Joshi DP (2014) Novel lipid signaling pathways in Alzheimer’s disease pathogenesis. Biochem Pharmacol 88:560–564CrossRefGoogle Scholar
  4. 4.
    Firuzi O, Zhou J, Chinnici CM, Wisniewski T, Praticò D (2008) 5-Lipoxygenase gene disruption reduces amyloid-beta pathology in a mouse model of Alzheimer’s disease. FASEB J 22:1169–1178. doi: 10.1096/fj.07-9131.com CrossRefPubMedGoogle Scholar
  5. 5.
    Joshi YB, Praticò D (2014) The 5-lipoxygenase pathway: oxidative and inflammatory contributions to the Alzheimer’s disease phenotype. Front Cell Neurosci 14:436. doi: 10.3389/fncel.2014.00436 Google Scholar
  6. 6.
    Ganguli M, Ratcliff G, Chandra V, Sharma S, Gilby J, Pandav R, Belle S, Ryan C et al (1995) A Hindi version of the MMSE: the development of a cognitive screening instrument for a largely illiterate rural elderly population in India. International Journal of Geriatric Psychiatry 10:367–377. doi: 10.1002/gps.930100505 CrossRefGoogle Scholar
  7. 7.
    O’Caoimh R, Timmons S, Molloy DW (2016) Screening for mild cognitive impairment: comparison of “MCI specific” screening instruments. J Alzheimers Dis 51:619–629. doi: 10.3233/JAD-150881 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34:939–944CrossRefPubMedGoogle Scholar
  9. 9.
    O’Bryant SE, Gupta V, Henriksen K, Edwards M, Jeromin A, Lista S, Bazenet C, Soares H et al (2015) STAR-B and BBBIG working groups. Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer’s disease research. Alzheimers Dement 11:549–560. doi: 10.1016/j.jalz.2014.08.099 CrossRefPubMedGoogle Scholar
  10. 10.
    Kumar R, Singh AK, Kumar M, Shekhar S, Rai N, Kaur P, Parshad R, Dey S (2016) Serum 5-LOX: a progressive protein marker for breast cancer and new approach for therapeutic target. Carcinogenesis 37:912–917. doi: 10.1093/carcin/bgw075 CrossRefPubMedGoogle Scholar
  11. 11.
    Ak S, Singh R, Naz F, Chauhan SS, Dinda A, Shukla AA, Gill K, Kapoor V et al (2012) Structure based design and synthesis of peptide inhibitor of human LOX-12: in vitro and in vivo analysis of a novel therapeutic agent for breast cancer. PLoS One 7:e32521. doi: 10.1371/journal.pone.0032521 CrossRefGoogle Scholar
  12. 12.
    König G, Masters CL, Beyreuther K (1990) Retinoic acid induced differentiated neuroblastoma cells show increased expression of the DA4 amyloid gene of Alzheimer’s disease and an altered splicing pattern. FEBS Lett 269:305–310. doi: 10.1016/0014-5793(90)81181-M CrossRefPubMedGoogle Scholar
  13. 13.
    Påhlman S, Ruusala AI, Abrahamsson L, Mattsson ME, Esscher T (1984) Retinoic acid-induced differentiation of cultured human neuroblastoma cells: a comparison with phorbolester-induced differentiation. Cell Differ 14:135–144CrossRefPubMedGoogle Scholar
  14. 14.
    Ju TC, Chen SD, Liu CC, Yang DI (2005) Protective effects of S-nitrosoglutathione against amyloid B-peptide neurotoxicity. Free Radic Biol Med 38:938–949. doi: 10.3233/JAD-121786 CrossRefPubMedGoogle Scholar
  15. 15.
    Chen YS, Chen SD, Wu CL, Huang SS, Yang DI (2014) Induction of sestrin2 as an endogenous protective mechanism against amyloid beta-peptide neurotoxicity in primary cortical culture. Exp Neurol 253:63–71. doi: 10.1016/j.expneurol.2013.12.009 CrossRefPubMedGoogle Scholar
  16. 16.
    Wu J, Yang H, Zhao Q, Zhang X, Lou Y (2016) Ginsenoside Rg1 exerts a protective effect against Aβ25-35induced toxicity in primary cultured rat cortical neurons through the NF-κB/NO pathway. Int J Mol Med 37:781–788. doi: 10.3892/ijmm.2016.2485 PubMedGoogle Scholar
  17. 17.
    Kumar R, Nigam N, Singh AP, Singh K, Subbarao N, Dey S (2016) Design, synthesis of allosteric peptide activator for human SIRT1 and its biological evaluation in cellular model of Alzheimer’s disease. Eur J Med Chem. doi: 10.1016/j.ejmech.2016.11.001 Google Scholar
  18. 18.
    Hooper C, Markevich V, Plattner F, Killick R, Schofield E, Engel T, Hernandez F, Anderton B et al (2007) Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur J Neurosci 25:81–86. doi: 10.1111/j.1460-9568.2006.05245.x CrossRefPubMedGoogle Scholar
  19. 19.
    Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH (1999) Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402:615–622CrossRefPubMedGoogle Scholar
  20. 20.
    Cruz JC, Tsai LH (2004) A Jekyll and Hyde kinase: roles for Cdk5 in brain development and disease. Curr Opin Neurobiol 14:390–394. doi: 10.1016/j.conb.2004.05.002 CrossRefPubMedGoogle Scholar
  21. 21.
    Yash BJ, Jin C, Domenico PD (2013) Knockout of 5-lipoxygenase prevents dexamethasone-induced tau pathology in 3xTg mice. Aging Cell 12:706–711. doi: 10.1111/acel.12096 CrossRefGoogle Scholar
  22. 22.
    Jin C, Praticò D (2013) 5-Lipoxygenase pharmacological blockade decreases tau phosphorylation in vivo: involvement of the cdk5 kinase. Neurobiol Aging 34:1549–1554. doi: 10.1016/j.neurobiolaging.2012.12.009 CrossRefGoogle Scholar
  23. 23.
    Chanu SI, Sarkar S (2016) Targeted downregulation of dMyc suppresses pathogenesis of human neuronal tauopathies in Drosophila by limiting heterochromatin relaxation and tau hyperphosphorylation. Mol Neurobiol. doi: 10.1007/s12035-016-9858-6 PubMedGoogle Scholar
  24. 24.
    Habchi J, Arosio P, Perni M, Costa AR, Yagi-Utsumi M, Joshi P, Chia S, Cohen SIA et al (2016) An anticancer drug suppresses the primary nucleation reaction that initiates the production of the toxic Ab42 aggregates linked with Alzheimer’s disease. Sci Adv 2:e1501244. doi: 10.1126/sciadv.1501244 CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Filali I, Romdhane A, Znati M, Jannet HB, Bouajila J (2016) Synthesis of new harmine isoxazoles and evaluation of their potential anti-Alzheimer, anti-inflammatory, and anticancer activities. Med Chem 12:184–190. doi: 10.2174/157340641202160209104115 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • Shashank Shekhar
    • 1
  • Saroj Kumar Yadav
    • 2
  • Nitish Rai
    • 1
  • Rahul Kumar
    • 1
  • Yudhishthir Yadav
    • 1
  • Manjari Tripathi
    • 3
  • Aparajit B. Dey
    • 2
  • Sharmistha Dey
    • 1
  1. 1.Department of BiophysicsAll India Institute of Medical SciencesNew DelhiIndia
  2. 2.Department of Geriatric MedicineAll India Institute of Medical SciencesNew DelhiIndia
  3. 3.Department of NeurologyAll India Institute of Medical SciencesNew DelhiIndia

Personalised recommendations